QIAGEN´s QuantiFERON®-TB Gold Plus gains approval in Canada
(WorldNews Netherlands)

Germantown, Maryland and Hilden, Germany, January 14th, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Health Canada regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic test to detect latent tuberculosis (TB) infection. QFT-Plus is the fourth generation of QIAGEN`s market-leading QuantiFERON-TB technology, combining a new flexible blood collection workflow with innovative CD8 T cell technology to enable comprehensive TB immune response detection. `QuantiFERON-TB Gold Plus sets a new benchmark in TB testing with the addition of specific CD8 T cell stimulating antigens. Many clinicians have already realized the...